Want to see BNBX full AI Analyst Report?
BNB Plus (BNBX) AI Stock Analysis
BNB Plus
(Other OTC:BNBX)
The score is primarily constrained by very weak financial performance—extreme losses and significant cash burn despite improved revenue—followed by bearish technical signals with price below all key moving averages. Valuation offers limited support due to negative earnings, while corporate events are mixed with both a strategic pivot and restructuring/leadership-change risks.
BNB Plus (BNBX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $210.49K
- Dividend Yield
- ―
- Average Volume (3M)
- 24.35K
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 1.16
- Revenue Growth
- -27.39%
- EPS Growth
- 99.29%
- Country
- US
- Employees
- 26
- Sector
- Financial
- Sector Strength
- 68
- Industry
- Biotechnology
BNB Plus Business Overview & Revenue Model
Company Description
BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Th...
BNB Plus Earnings Call Summary
The earnings call highlighted significant progress in revenue growth, operational efficiencies, and strategic focus on the LineaRx subsidiary. However, it also outlined challenges such as an increased net loss, a major business segment exit, and ongoing concerns about the company's financial stability. Despite these challenges, the strategic restructuring and new opportunities in the LineaRx segment suggest a cautiously optimistic outlook.
Q1-2025 Updates
Positive Updates
Negative Updates
Company Guidance
During the Applied DNA Sciences First Quarter Fiscal 2025 Financial Results call, the company announced several key financial and strategic updates. Total revenues for the first quarter increased to $1.2 million from $891,000 in the same period of fiscal 2024, primarily due to higher product revenue from the DNA tagging business segment and increased textiles isotopic testing services revenue. The company reported an operating loss of $3 million, an improvement from the $3.8 million loss in the prior year, primarily due to lower selling, general, and administrative costs. However, the net loss widened to $2.7 million compared to $1.1 million the previous year, with adjusted EBITDA improving to negative $2.9 million from negative $3.2 million. Cash and cash equivalents as of December 31 totaled $9.3 million, up from $6.4 million at the end of September 2024, reflecting proceeds from an October offering. As part of a strategic restructuring aimed at focusing on its LineaRx subsidiary, Applied DNA announced its exit from the DNA tagging and security products and services business segment and a 20% workforce reduction, with a one-time charge of approximately $300,000 anticipated. The company emphasized LineaRx's growth potential, highlighting its GMP Site One certification and the introduction of new products like Linea Donor DNA for CRISPR applications.
BNB Plus Financial Statement Overview
Summary
Despite a sharp TTM revenue rebound (+198.5%), profitability and cash generation are major negatives: very low gross margin (~23%), extreme operating and net losses (EBIT margin ~-1,298%, net margin ~-1,516%), and deeply negative operating/free cash flow (~-$13.8M). The balance sheet is a relative strength with minimal debt and higher equity, but returns remain deeply negative (ROE ~-320%).
Income Statement
18Very NegativeBalance Sheet
62PositiveCash Flow
22Negative| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.09M | 2.14M | 3.43M | 13.37M | 18.17M | 9.03M |
| Gross Profit | 910.30K | 838.91K | 1.02M | 5.53M | 5.05M | 4.93M |
| EBITDA | -34.70M | -15.26M | -13.33M | -9.59M | -12.68M | -11.68M |
| Net Income | -34.48M | -15.16M | -6.99M | -9.95M | -8.38M | -16.03M |
Balance Sheet | ||||||
| Total Assets | 13.63M | 4.44M | 12.79M | 13.65M | 22.27M | 14.42M |
| Cash, Cash Equivalents and Short-Term Investments | 949.09K | 1.67M | 6.43M | 7.15M | 15.22M | 6.55M |
| Total Debt | 0 | 193.25K | 739.16K | 1.24M | 0 | 0 |
| Total Liabilities | 1.50M | 2.50M | 3.82M | 8.78M | 9.36M | 3.30M |
| Stockholders Equity | 12.51M | 2.30M | 9.14M | 4.95M | 12.91M | 11.11M |
Cash Flow | ||||||
| Free Cash Flow | -13.80M | -12.83M | -14.12M | -6.30M | -9.47M | -15.94M |
| Operating Cash Flow | -13.79M | -12.52M | -13.71M | -6.22M | -8.98M | -13.39M |
| Investing Cash Flow | -2.96M | -292.12K | -407.90K | -1.10M | -489.55K | -2.55M |
| Financing Cash Flow | 9.96M | 8.05M | 13.40M | 0 | 18.13M | 14.70M |
BNB Plus Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNBX, the sentiment is Negative. The current price of 0.10 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.13, and below the 200-day MA of 0.43, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 46.20 is Neutral, neither overbought nor oversold. The STOCH value of 32.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNBX.
BNB Plus Risk Analysis
BNB Plus disclosed 41 risk factors in its most recent earnings report. BNB Plus reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksBNB Plus Peers Comparison
Overall Rating
NDRA51Neutral
INBS46Neutral
ISPC43Neutral- BNBX41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 68Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% |
| NDRA | 51Neutral | $7.51M | -0.75 | -224.80% | ― | ― | 98.17% |
| INBS | 46Neutral | $5.84M | -0.21 | -170.36% | ― | 38.09% | 54.22% |
| ISPC | 43Neutral | $2.03M | -0.02 | -524.37% | ― | -92.11% | 86.78% |
| BNBX | 41Neutral | $495.78K | -0.00 | -337.10% | ― | -27.39% | 99.29% |
* Financial Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BNBX | Bnb Plus Corp. | 0.10 | -3.23 | -97.03% | |
| NDRA | Endra Life Sciences | 4.73 | -0.79 | -14.31% | |
| INBS | Intelligent Bio Solutions Inc. | 1.97 | -5.87 | -74.87% | |
| ISPC | Ispecimen Inc | 0.81 | -24.95 | -96.84% | |
| BGLC | Bionexus Gene Lab Corporation | 0.83 | -4.41 | -84.16% |
BNB Plus Corporate Events
BNB Plus pivots to institutional blockchain and AI
PositiveOn October 2, 2026, BNB Plus Corp. announced a strategic shift from a passive digital asset treasury focused on the BNB Chain to an operating model building infrastructure for financial institutions and enterprises to adopt blockchain and agentic AI....
BNB Plus Amends Registration Rights Agreement for Flexibility
NeutralBNB Plus is party to a Registration Rights Agreement governing how holders of its private-offering securities can obtain SEC registration for resale. The agreement covers “Registrable Securities” held by purchasers owning a majority inter...
BNB Plus Reshapes Board With New Investor-Linked Directors
NeutralOn September 2, 2026, BNB Plus Corp. announced that directors Robert B. Catell, Joseph D. Ceccoli and Dr. Yacov Shamash resigned from the board effective September 3, 2026, with the company stating the departures were not due to disagreements over op...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 17, 2026